Clinical Trials Logo

SLL clinical trials

View clinical trials related to SLL.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00980395 Completed - Lymphoma Clinical Trials

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

VCR
Start date: July 7, 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with cladribine and rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine and rituximab works in treating patients with advanced mantle cell lymphoma or indolent lymphoma.

NCT ID: NCT00546793 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.